Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS. Phase II multicenter randomized trial to assess the efficacy and safety of first line ...

New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...

ORR of 67% (6 of 9) in MAPK inhibitor (MAPKi)-naïve adults with V600-mutated primary recurrent central nervous system tumors, with a median duration of response (mDOR) of 13.9 months ORR of 42% (10 of ...

The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers. The Food and Drug ...

CHICAGO —Targeted therapy achieved significantly higher responses rates and longer progression-free survival (PFS) when compared with standard chemotherapy in pediatric patients with BRAF V600-mutant ...

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract ...

Drug is indicated for patients identified by Roche’s cobas 4800 mutation test. The European Commission approved Roche and Plexxikon’s melanoma drug Zelboraf (vemurafenib) for the treatment of BRAF ...

Dabrafenib has been recommended by NICE for adults with advanced non-small-cell lung cancer with a BRAF V600 mutation, with the regulator saying that hundreds are set to benefit. People with advanced ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced new nonclinical data related to plixorafenib (FORE8394; formerly PLX8394), the company's novel, investigational, small-molecule, ...

WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science ...